Rabbit anti-Human SIGLEC9 Monoclonal Antibody for Flow Cytometry - Q9Y336

Core Product Specifications and Parameters

Biological Background: SIGLEC9 Function and Localization

• Sialic acid-binding Ig-like lectin 9 (SIGLEC9, also known as CD329 or FOAP-9) is a putative adhesion molecule that mediates sialic-acid-dependent binding to cells, preferentially recognizing α-2,3- or α-2,6-linked sialic acid.
• The ligand-binding site may be masked in cis by interactions with sialic acids on the same cell surface, potentially modulating cellular adhesion and signaling.
• SIGLEC9 is a member of the immunoglobulin superfamily and contains one Ig-like V-type domain and two Ig-like C2-type domains, characteristic of the sialic acid-binding lectin family.
• It is expressed on peripheral blood leukocytes, notably neutrophils and monocytes, but not eosinophils; also found in liver, fetal liver, bone marrow, placenta, spleen, and at lower levels in many other tissues.
• The protein is a single-pass type I membrane protein, with an extracellular region containing the sialic acid recognition site and a cytoplasmic tail that may participate in inhibitory signaling.
• Post-translational modifications include N-linked glycosylation and disulfide bond formation, which are critical for structural stability and function.
• Alternative splicing generates multiple isoforms, and the protein is subject to proteolytic shedding, which may regulate its surface expression and generate soluble SIGLEC9.
• As a lectin, SIGLEC9 is involved in cell-cell interactions and immune modulation, and its dysregulation has been implicated in inflammatory and autoimmune conditions.

Experimental Guidance and Technical Tips

• This antibody was raised against a recombinant protein corresponding to the extracellular domain (amino acids 18-348) of human SIGLEC9; it is expected to recognize the native, surface-expressed form of the protein.
• For flow cytometry, consider titrating the antibody to determine the optimal staining concentration for your cell type and assay conditions, as excessive antibody may increase background or affect signal-to-noise ratio.
• Due to potential cis-masking of SIGLEC9 epitopes by sialic acids on the cell surface, enzymatic desialylation (e.g., neuraminidase treatment) may be tested to enhance antibody binding in certain experimental setups; however, validate in the relevant sample system first.
• Since SIGLEC9 is expressed predominantly on neutrophils and monocytes, include appropriate gating strategies and lineage markers to confirm specificity in mixed leukocyte populations.
• Fluorescence compensation is required when using in combination with other fluorophores; use single-stained controls to set compensation matrices accurately.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one-stop partner for IVD raw-material sourcing, from validated antibody pairs and optimized monoclonal/polyclonal antibodies to bulk ancillary reagents and rare target raw-material procurement. As a B2B supply specialist, we support diagnostic manufacturers, labs, and research institutes in immunology and cell adhesion research areas by offering reliable access to well-characterized reagents like this anti-SIGLEC9 antibody. Contact us to streamline your supply chain and accelerate development from concept to clinic.